Starpharma Holdings Ltd (ASX: SPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Starpharma Holdings Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $317.81 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 407.44 million
Earnings per share -0.044
Dividend per share N/A
Year To Date Return -41.79%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Starpharma Holdings Ltd (ASX: SPL)
Latest News

Medical professionals cheering good news. pro medicus
Healthcare Shares

Here’s why the Starpharma (ASX:SPL) share price is having such a stellar end to the week

The global biopharmaceutical company has great news for ASX investors today.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

4 ASX healthcare shares at 52-week lows

A number of ASX healthcare shares just hit 52-week lows.

Read more »

Scientists in white coats look disappointed as the Starpharma share price falls today
Healthcare Shares

Here’s why the Starpharma (ASX:SPL) share price is tumbling 8% today

Starpharma has responded to a media article published today.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Starpharma (ASX:SPL) share price lifts on Omicron study results

Omicron has been dealt another blow thanks to Starphama's latest study results.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Share Market News

Not enough: Starpharma (ASX:SPH) share price plunges despite 200% revenue growth

Starpharma shares closed in the red on Monday as the company released its financial results for the half-year ended 31…

Read more »

medical researcher holding laboratory equipment
Healthcare Shares

What is happening to the Starpharma (ASX:SPL) share price today?

Starpharma is complementing COVID-19 vaccines with its anti-viral nasal spray

Read more »

a group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Starpharma (ASX:SPL) share price shoots 6% higher on Roche agreement

The company's shares are on the move today.

Read more »

Young woman wearing glasses and red top looks at laptop happily as Starpharma price rises
Healthcare Shares

Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch

What's happening with the biopharmaceutical company?

Read more »

SPL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Starpharma Holdings Ltd

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating and VIRALEZE an antiviral nasal spray.

SPL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $0.78 $-0.02 -2.50% 227,100 $0.81 $0.82 $0.78
12 May 2022 $0.80 $0.01 1.27% 515,040 $0.78 $0.80 $0.76
11 May 2022 $0.79 $0.02 2.58% 239,197 $0.78 $0.79 $0.76
10 May 2022 $0.78 $0.02 2.63% 322,790 $0.73 $0.78 $0.73
09 May 2022 $0.76 $-0.05 -6.13% 452,182 $0.80 $0.80 $0.75
06 May 2022 $0.82 $0.00 0.00% 337,934 $0.79 $0.82 $0.78
05 May 2022 $0.81 $0.01 1.24% 104,667 $0.81 $0.83 $0.81
04 May 2022 $0.81 $-0.02 -2.41% 166,700 $0.83 $0.83 $0.80
03 May 2022 $0.83 $0.00 0.00% 125,623 $0.83 $0.83 $0.81
02 May 2022 $0.83 $-0.02 -2.35% 177,192 $0.84 $0.84 $0.82
29 Apr 2022 $0.85 $0.05 6.25% 323,722 $0.84 $0.86 $0.82
28 Apr 2022 $0.80 $-0.04 -4.76% 329,332 $0.84 $0.88 $0.80
27 Apr 2022 $0.84 $0.04 5.00% 98,376 $0.84 $0.84 $0.81
26 Apr 2022 $0.80 $-0.02 -2.42% 1,481,904 $0.82 $0.84 $0.79
22 Apr 2022 $0.83 $-0.02 -2.37% 408,007 $0.83 $0.84 $0.82
21 Apr 2022 $0.85 $0.01 1.19% 126,099 $0.84 $0.86 $0.84
20 Apr 2022 $0.84 $0.00 0.00% 252,163 $0.84 $0.85 $0.83

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Dec 2021 Jacinth (Jackie) Fairley Issued 493 $594,498
Issue of securities. 5,502,890 - Performance Rights
01 Oct 2021 Jacinth (Jackie) Fairley Cancelled 224 $292,125
Cancellation of securities. 5,009,530 - Performance Rights
31 Aug 2021 Zita Peach Buy 8 $10,042
On-market trade.
30 Aug 2021 Jacinth (Jackie) Fairley Buy 50 $57,979
On-market trade.
27 Aug 2021 Robert Thomas Buy 25 $28,990
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Zita Peach Non-Executive Director Oct 2011
Ms Peach has more than 25 years of executive commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries. She worked for CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Ms Peach's most recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, provider of pharmaceutical products and medical devices to hospitals. Previously, Ms Peach was Vice President, Business Development, for CSL Limited, a position she held for ten years. Ms Peach has substantial international and local experience in the areas of pharmaceutical/medical device product development, commercialisation of products and technologies, marketing and sales, licensing, M&A and international expansions. She has overseen manufacturing, logistics, regulatory affairs, quality assurance, clinical services, human resources, finance, information technology, public policy, business development, marketing and sales at Managing Director and CEO level. Ms Peach is Chairman of Pacific Smiles Group Limited, and a Non-Executive Director of the ASX-listed Monash IVF Group Limited, and Visioneering Technologies, Inc. Ms Peach is also a member of the Hudson Institute of Medical Research Board. Currently, she is Director of Monash IVF Group Limited, Visioneering Technologies, Inc. and Pacific Smiles Group Limited. She is a member of Risk committee.
Mr Robert Bain Thomas Non-Executive DirectorNon-Executive Chairman Dec 2013
Mr Thomas has a background in financial services and capital markets and is a non-executive director of several Australian listed companies. Formerly Mr Thomas was a Partner of Potter Partners (now UBS) where he was also Head of Research. Mr Thomas is the former Chief Executive Officer (CEO) of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL and HeartWare International Inc, the second largest global manufacturer of left ventricular assist heart pumps. Mr Thomas is currently a non-executive director of ASX listed Biotron Limited and Clarity Pharmaceuticals Limited. Mr Thomas is also Chair of AusBio Ltd, Grahger Retail Securities, Co-Chair of the State Library of NSW Foundation and a director of O'Connell Street Associates. He has experience in Mergers & Acquisition (M&A) and capital markets including advising on the floats of Commonwealth Bank of Australia and Qantas, and experience in Audit and Risk Management. Mr Thomas is also approved under the NSW prequalification scheme for Audit and Risk Committee Independent Chairs and Members for government/public sector agencies and has previously served as the Chairman of the Audit and Risk Committee of Virgin Australia Limited (for 11 years), HeartWare International Inc, REVA Medical Limited and the State Library of NSW. He is a member of Risk committee.
Mr David McIntyre Non-Executive Director Mar 2020
Mr McIntyre has more than 20 years of experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. Mr McIntyre's experience also includes seven years as a Partner at Apple Tree Partners, a venture capital and growth equity fund, giving him a deep knowledge of, and extensive contacts, in the US pharma, medical device and biotech markets. During this time, Mr McIntyre served as a nonexecutive director of several United States life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG in M&A, initial public offerings, and corporate law and also held various senior finance roles in both multi-national companies and small growth companies. Mr McIntyre has experience in the areas of accounting/corporate finance, audit and risk, strategy and risk management. He is chair of Risk committee.
Dr Jacinth (Jackie) Kincaid Fairley Chief Executive OfficerExecutive Director Jul 2006
Dr Fairley has more than 30 years of experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL Limited (CSL) and Faulding (now Pfizer). In those roles Dr Fairley had responsibilities which included clinical, regulatory, business development, product development management and general management. At Faulding Dr Fairley was responsible for Global Product Development, Regulatory Affairs and Business Development for Faulding's Hospital Business which operated in more than 60 countries Dr Fairley is a non-executive director of listed investment company Mirrabooka Investments Limited and Chairman of the Invest Victoria Advisory Board. Dr Fairley is a past member of the Federal Government's Commonwealth Science Council and Pharmaceutical Industry Working Group; the Federal Ministerial Biotechnology Advisory Council and previously served on the Board of Melbourne Business School for 10 years.
Ms Lynda Cheng Non-Executive Director Aug 2021
Ms Cheng has more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt Holdings and 10 years in investment banking. Ms Cheng is currently Director of Corporate Development and Mergers & Acquisitions at Visy Industries / Pratt Holdings and has held various other roles in the group including CFO. She began her career as a lawyer at Blake Dawson, before moving into investment banking with J.P. Morgan in their Melbourne, Sydney, San Francisco and New York offices. Ms Cheng is currently a non-executive director of Export Finance Australia and a member of the Wesley College Council. Ms Cheng previously served as a member of the Australian Government's International Development Policy Expert Panel and Deputy Chair and Chair of the Finance, Audit and Risk Committee of South East Water. She will also appointed as member of Risk Committee of SPL effective 01/08/2021.
Dr Jeff Davies Non-Executive Director Apr 2022
Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland. His experience spans R&D, business operations, drug development and product commercialisation.
Mr Nigel Baade Chief Financial OfficerCompany Secretary Jan 2009
-
Nigel Baade Chief Financial OfficerCompany Secretary
-
A Eglezos VP Business Development
-
J R Paull VP Development & Regulatory Affairs
-
D J Owen VP Research
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 125,584,383 30.93%
JP Morgan Nominees Australia Pty Limited 49,079,638 12.00%
Citicorp Nominees Pty Limited 23,997,000 5.91%
National Nominees Limited 11,486,806 2.83%
BNP Paribas Noms Pty Ltd <Drp> 9,955,488 2.45%
T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> 4,970,000 1.22%
BNP Paribas Nominees Pty Ltd Acf Clearstream 4,408,891 1.09%
Mirrabooka Investments Limited 4,067,044 1.00%
Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> 3,361,550 0.83%
Ms Jacinth Fairley 3,252,386 0.80%
Mr Kingsley Bryan Bartholomew 3,054,025 0.75%
Mr Peter Murray Jackson 3,020,000 0.74%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 2,950,611 0.73%
BNP Paribas Nominees Pty Ltd <IN AU Noms Retail Client> 2,766,480 0.68%
HSBC Custody Nominees (Australia) Limited A/C 2 2,484,209 0.61%
Dollar Coin Investments Pty Ltd <Cousins Discretionary A/C> 1,990,030 0.49%
Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation> 1,669,950 0.41%
Merrill Lynch (Australia) Nominees Pty Limited 1,540,474 0.38%
Commonwealth Scientific and Industrial Research Organisation 1,448,798 0.36%
Mr David Michael Hosey + Mrs Andrea Jane Hosey 1,429,422 0.35%

Profile

since

Note